Thermo Fisher Launches TacroType Test to Personalize Tacrolimus Dosing for Transplant Patients
Published: 02 Mar 2026
Author: Precedence Research
Thermo Fisher Scientific has recently launched the TacroType Pharmacogenetic Test, which is a highly innovative diagnostic solution. That would assist clinicians in identifying the optimal initial dose of tacrolimus, a foundation immunosuppressive treatment in organ transplantation. The test helps to minimize the chances of under- or overdosing individual patients during a critical initial post-transplant phase. It will determine how the medication is metabolized by the individual patient based on their genetic profile. This innovation indicates the rising trend of integrating pharmacogenetics into regular transplant management, where accuracy and time play a crucial role in patient survival and prolonged graft survival.
The TacroType test is a rapid and quantitative polymerase chain reaction (qPCR) method that provides accurate genotyping in a clinically significant time. The application of TacroType goes beyond enhancing early dosing choices, as the introduction of the transplant diagnostics transformation is underscored. There is an increasing demand in hospitals and transplant institutes to find tools that minimize the variability of care and uphold the use of standardized and evidence-based treatment plans.
The proposed new offering by Thermo Fisher could help to minimize trial and error corrections to achieve a rapid time to therapeutic range. Thus, reducing the time of graft survival and patient outcomes. Furthermore, such specific diagnostic tools are a good step in a healthcare setting where even a small increase in post-transplant stability can make a major difference in the long-term outcomes.
Tina Liedtky, the President of Transplant Diagnostics business at Thermo Fisher Scientific, emphasized the time factor of transplant care, as she says that every day counts after a patient has been provided with a new organ. She said that the TacroType test can give the clinician valuable information at the very outset so that they can offer more efficient and personal treatment within a critical period of recovery.
Liedtky also reported on the demonstration of an increasing role of pharmacogenetics in transplant medicine, as shown by the launch, which provides clinicians with a new piece of information to base immunosuppressive therapy on a specific biological profile of a particular patient.